Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD,

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + Ribavirin in HCV GT 1,4 SOLAR-1 (Post Transplant) Phase 2 Treatment Naïve and Treatment.
Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.
Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6): doi: /M
Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):
Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.
Value in Health Regional Issues
Volume 16, Issue 6, Pages (September 2013)
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
129 patients with chronic hepatitis C
Design Randomisation 1 : 1 Open-label W16 W24 > 18 years
Phase 3 Treatment-Naïve and Treatment-Experienced
HCV Studies Performed on New Iranian DAA Drugs
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving  Jagpreet Chhatwal, Tianhua He, Chin Hur, Maria.
The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options  Axel.
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection  Yi–Cheng Chen, I.–Shyan Sheen,
Volume 69, Issue 2, Pages (August 2018)
Value in Health Regional Issues
Value in Health Regional Issues
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis 
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Volume 153, Issue 4, Pages (October 2017)
Value in Health Regional Issues
Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus  Amit G. Singal, Michael.
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Phase 2 Treatment Naïve and Treatment Experienced
Michael Biermer, Thomas Berg  Gastroenterology 
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
Clinical outcome after SVR: ANRS CO22 HEPATHER
Value in Health Regional Issues
Volume 73, Pages S53-S68 (April 2008)
An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System  Carine Raquel Blatt, PhD, Noemia Liege Maria da Cunha Bernardo, MSc,
Hepatitis C Virus Infection in the Older Patient
Acute hepatitis C: Current status and remaining challenges
Advancing the Visibility, Impact, and Quality Metrics of Value in Health Regional Issues  Dan Greenberg, PhD, Imre Boncz, MD, MSc, PhD, Habil, Ahmed Awaisu,
Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M
Value in Health Regional Issues
Volume 61, Issue 3, Pages (September 2014)
Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns 
Volume 68, Issue 4, Pages (April 2018)
Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective  Bruno Salgado Riveros,
Value in Health Regional Issues
Volume 136, Issue 5, Pages (May 2009)
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Cost-Effectiveness Analysis Expands its Reach Worldwide
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus–related cirrhosis  Derek Patel, Norah A. Terrault, Francis.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences  Zobair M. Younossi, Aybike Birerdinc,
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Hepatitis C treatment in patients with kidney disease
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection  Yi–Cheng Chen, I.–Shyan Sheen,
Volume 124, Issue 3, Pages (March 2003)
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD, Asmaa Aburawash, BSc, Emam Waked, MD  Value in Health Regional Issues  Volume 13, Pages 7-15 (September 2017) DOI: 10.1016/j.vhri.2017.03.012 Copyright © 2017 Terms and Conditions

Fig. 1 Markov process model for noncirrhotic patients. DCC, decompensated cirrhosis; F3, METAVIR fibrosis score F3; F4, METAVIR fibrosis score F4; HCC, hepatocellular carcinoma; LT, liver transplant. Value in Health Regional Issues 2017 13, 7-15DOI: (10.1016/j.vhri.2017.03.012) Copyright © 2017 Terms and Conditions

Fig. 2 Markov process model for cirrhotic patients. DCC, decompensated cirrhosis; F4, METAVIR fibrosis score F4; HCC, hepatocellular carcinoma; LT, liver transplant. Value in Health Regional Issues 2017 13, 7-15DOI: (10.1016/j.vhri.2017.03.012) Copyright © 2017 Terms and Conditions

Fig. 3 Results of one-way sensitivity analysis for noncirrhotic patients. (A) SOF + DCV vs. SOF + pegIFN + RBV. (B) SOF + LDV + RBV vs. SOF + pegIFN + RBV. (C) SOF + RBV vs. SOF + pegIFN + RBV. DCV, daclatasvir; HCC, hepatocellular carcinoma; LDV, ledipasvir; pegIFN, pegylated interferon alfa; QALY, quality-adjusted life-year; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response. Value in Health Regional Issues 2017 13, 7-15DOI: (10.1016/j.vhri.2017.03.012) Copyright © 2017 Terms and Conditions

Fig. 4 Results of one-way sensitivity analysis for cirrhotic patients. (A) SOF + DCV vs. SOF + pegIFN + RBV. (B) SOF + LDV + RBV vs. SOF + pegIFN + RBV. (C) SOF + RBV vs. SOF + pegIFN + RBV. DCC, decompensated cirrhosis; DCV, daclatasvir; HCC, hepatocellular carcinoma; LDV, ledipasvir; pegIFN, pegylated interferon alfa; QALY, quality-adjusted life-year; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response. Value in Health Regional Issues 2017 13, 7-15DOI: (10.1016/j.vhri.2017.03.012) Copyright © 2017 Terms and Conditions

Fig. 5 Incremental cost-effectiveness plane for SOF + DCV vs. SOF + pegIFN + RBV in noncirrhotic patients. DCV, daclatasvir; pegIFN, pegylated interferon alfa; RBV, ribavirin; SOF, sofosbuvir. Value in Health Regional Issues 2017 13, 7-15DOI: (10.1016/j.vhri.2017.03.012) Copyright © 2017 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.